Biotech · Private company · Durham, NC, US
Eydis Bio, Inc.
Track this companyFree. Adds Eydis Bio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards5
- Development of a novel, orally bioavailable, TAK1 inhibitor for the treatment of chemotherapy-induced peripheral neuropathyFiscal year 2026 · $406.5KNIH RePORTER 1R43CA310084-01 · fetched Nov 12, 2026
- Novel compounds for the treatment of systemic sclerosis-associated interstitial lung diseaseFiscal year 2025 · $1.4MNIH RePORTER 5R44HL170834-02 · fetched Nov 12, 2026
- Discovery and Development of Oral Small-molecule Direct-acting Antivirals Fiscal year 2025 · $499.8KNIH RePORTER 75N93025C00040-0-9999-1 · fetched Nov 12, 2026
- Development of orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's DiseaseFiscal year 2024 · $506.3KNIH RePORTER 1R41AG090212-01 · fetched Nov 12, 2026
- Novel compounds for the treatment of systemic sclerosis-associated interstitial lung diseaseFiscal year 2024 · $1.2MNIH RePORTER 1R44HL170834-01A1 · fetched Nov 12, 2026